NICE Unable To Recommend Golimumab For Psoriatic Arthritis - Wall Street Journal

NICE Unable To Recommend Golimumab For Psoriatic Arthritis Wall Street Journal ... or NICE, said Wednesday it is unable to recommend golimumab for the treatment of active and progressive psoriatic arthritis in adults when the response ... British cost body rebuffs J&J's Simponi drugLondon South East all 7 news articles »

Arthritis sufferers finally granted new treatment - New Zealand Doctor Online

TopNews United Kingdom

Arthritis sufferers finally granted new treatment New Zealand Doctor Online Arthritis New Zealand welcomes PHARMAC's announcement that a second biologic option for patients in New Zealand with severe Psoriatic Arthritis (PA), ... The Symptoms and Treatment Options for Psoriatic ArthritisEmpowHer Arthritis sufferers finally granted new treatmentTopNews United Kingdom all 6 news articles »

EADV: Study Points to Optimal Etanercept Regimen for Psoriasis, PsA - Skin and Allergy News Digital Network

Skin and Allergy News Digital Network

EADV: Study Points to Optimal Etanercept Regimen for Psoriasis, PsA Skin and Allergy News Digital Network GOTHENBURG, Sweden - In patients with both plaque psoriasis and psoriatic arthritis, initial treatment with etanercept at 50 mg twice weekly resulted in ... and more »

Surveyed Dermatologists and Rheumatologists Expect to Increase Their First ... - PR Newswire (press release)

Surveyed Dermatologists and Rheumatologists Expect to Increase Their First ... PR Newswire (press release) According to the new report entitled Treatment Algorithms in Psoriatic Arthritis, Simponi's favorable (once per month) dosing compared with other TNF-alpha ... and more »